Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 592 single-ascending dose study in healthy subjects
NCT05873907Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efavaleukin alfa in chronic graft-versus-host disease (cGVHD) (9 arms), sponsored by Amgen. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events, Number of Participants with Anti-AMG 592 Antibodies and 3 more. Started Oct 2015; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05873907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873907.